OVOL2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: Human cerebella tissue, Human cerebrum tissue, Human skin tissue, NIH/3T3 cell, SKOV3 cell lysates, Primary antibody: P09886(OVOL2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09886(OVOL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The OVOL2 antibody is a crucial tool in studying the OVO-like 2 (OVOL2) protein, a transcription factor belonging to the OVO family characterized by conserved C2H2 zinc finger DNA-binding domains. OVOL2 plays a pivotal role in regulating epithelial-mesenchymal transition (EMT), cell differentiation, and tissue development. It acts as a transcriptional repressor, often inhibiting EMT by suppressing pro-mesenchymal genes (e.g., ZEB1. SNAI1) while promoting epithelial markers (e.g., E-cadherin). This dual function links OVOL2 to critical processes in embryonic development, tissue homeostasis, and cancer progression, where its dysregulation is associated with metastasis and poor prognosis.

Researchers use OVOL2 antibodies to detect protein expression, localization, and dynamics in various models, including cancer cell lines, stem cells, and developing tissues. These antibodies are essential in techniques like Western blotting, immunohistochemistry, and immunofluorescence. High-quality OVOL2 antibodies exhibit specificity for distinct isoforms or conserved regions, minimizing cross-reactivity with homologous proteins like OVOL1 or OVOL3. Validated applications and species reactivity (human, mouse, rat) are key considerations.

Understanding OVOL2's role via antibody-based studies has advanced insights into organogenesis, wound healing, and therapeutic targeting of EMT-driven pathologies. However, antibody validation remains critical to ensure reproducibility, given OVOL2's context-dependent expression and post-translational modifications.